_id
69105657ccc777a4e85d561e
Ticker
CTBO
Name
Cantabio Pharmaceuticals Inc
Exchange
PINK
Address
2225 East Bayshore Road, Palo Alto, CA, United States, 94303
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.cantabio.com
Description
Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.
Last Close
1.01
Volume
24
Current Price
1.01
Change
0
Last Updated
2026-01-02T12:08:03.615Z
Image
data:image/webp;base64,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
Ipo Date
-
Market Cap
563600
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2018-12-31
Revenue
0
Cost Of Revenue
0
Gross Profit
0
Operating Expenses
240192
Operating Income
-240192
Interest Expense
347200
Pretax Income
342967
Net Income
342967
Eps
19.598114285714285
Dividends Per Share
0
Shares Outstanding
22544
Income Tax Expense
0
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
583159
Cash
283371
Short Term Investments
0
Receivables
0
Inventories
0
Total Current Assets
325871
Property Plant Equipment
0
Total Assets
325871
Payables
242006
Short Term Debt
0
Long Term Debt
0
Total Liabilities
2214785
Equity
-1888914
Bs_currency_symbol
USD
Depreciation
0
Change In Working Capital
-
Cash From Operations
-258156
Capital Expenditures
0
Cash From Investing
0
Cash From Financing
520000
Net Change In Cash
261844
Cf_currency_symbol
USD
PE
-
PB
-0.009357228545079341
ROE
-18.156835091486432
ROA
105.24624774834213
FCF
-258156
Fcf Percent
-
Piotroski FScore
1
Health Score
44
Deep Value Investing Score
3
Defensive Investing Score
6
Dividend Investing Score
3.5
Economic Moat Investing Score
7
Garp Investing Score
0.5
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
1.5
Quality Investing Score
3
Value Investing Score
2.5
Quarters > 0 > quarter
2018-12-31
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
0
Quarters > 0 > income Statement > gross Profit
0
Quarters > 0 > income Statement > operating Expenses
240192
Quarters > 0 > income Statement > operating Income
-240192
Quarters > 0 > income Statement > interest Expense
347200
Quarters > 0 > income Statement > pretax Income
342967
Quarters > 0 > income Statement > net Income
342967
Quarters > 0 > income Statement > eps
19.598114285714285
Quarters > 0 > income Statement > dividends Per Share
0
Quarters > 0 > income Statement > shares Outstanding
17500
Quarters > 0 > income Statement > income Tax Expense
0
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
583159
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
283371
Quarters > 0 > balance Sheet > short Term Investments
0
Quarters > 0 > balance Sheet > receivables
0
Quarters > 0 > balance Sheet > inventories
0
Quarters > 0 > balance Sheet > total Current Assets
325871
Quarters > 0 > balance Sheet > property Plant Equipment
0
Quarters > 0 > balance Sheet > total Assets
325871
Quarters > 0 > balance Sheet > payables
242006
Quarters > 0 > balance Sheet > short Term Debt
0
Quarters > 0 > balance Sheet > long Term Debt
0
Quarters > 0 > balance Sheet > total Liabilities
2214785
Quarters > 0 > balance Sheet > equity
-1888914
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
342967
Quarters > 0 > cash Flow > depreciation
0
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-258156
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
0
Quarters > 0 > cash Flow > cash From Financing
520000
Quarters > 0 > cash Flow > net Change In Cash
261844
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
19.598114285714285
Quarters > 0 > ratios > PB
-0.009357228545079341
Quarters > 0 > ratios > ROE
-18.156835091486432
Quarters > 0 > ratios > ROA
105.24624774834213
Quarters > 0 > ratios > FCF
-258156
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
44
Quarters > 1 > quarter
2018-09-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
0
Quarters > 1 > income Statement > gross Profit
0
Quarters > 1 > income Statement > operating Expenses
234131
Quarters > 1 > income Statement > operating Income
-234131
Quarters > 1 > income Statement > interest Expense
288693
Quarters > 1 > income Statement > pretax Income
-568616
Quarters > 1 > income Statement > net Income
-568616
Quarters > 1 > income Statement > eps
-0.01
Quarters > 1 > income Statement > dividends Per Share
0
Quarters > 1 > income Statement > shares Outstanding
56861600
Quarters > 1 > income Statement > income Tax Expense
0
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-334485
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
21527
Quarters > 1 > balance Sheet > short Term Investments
0
Quarters > 1 > balance Sheet > receivables
0
Quarters > 1 > balance Sheet > inventories
0
Quarters > 1 > balance Sheet > total Current Assets
21527
Quarters > 1 > balance Sheet > property Plant Equipment
0
Quarters > 1 > balance Sheet > total Assets
21527
Quarters > 1 > balance Sheet > payables
341354
Quarters > 1 > balance Sheet > short Term Debt
0
Quarters > 1 > balance Sheet > long Term Debt
0
Quarters > 1 > balance Sheet > total Liabilities
2444409
Quarters > 1 > balance Sheet > equity
-2422882
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-568616
Quarters > 1 > cash Flow > depreciation
0
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-163709
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
0
Quarters > 1 > cash Flow > cash From Financing
520000
Quarters > 1 > cash Flow > net Change In Cash
-163709
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.01
Quarters > 1 > ratios > PB
-23.703265780174192
Quarters > 1 > ratios > ROE
23.468579980370485
Quarters > 1 > ratios > ROA
-2641.4084637896594
Quarters > 1 > ratios > FCF
-163709
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
39
Quarters > 2 > quarter
2018-06-30
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
0
Quarters > 2 > income Statement > gross Profit
0
Quarters > 2 > income Statement > operating Expenses
235873
Quarters > 2 > income Statement > operating Income
-235873
Quarters > 2 > income Statement > interest Expense
348992
Quarters > 2 > income Statement > pretax Income
-466865
Quarters > 2 > income Statement > net Income
-466865
Quarters > 2 > income Statement > eps
-0.01999995716115545
Quarters > 2 > income Statement > dividends Per Share
0
Quarters > 2 > income Statement > shares Outstanding
23343300
Quarters > 2 > income Statement > income Tax Expense
0
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-230992
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
185236
Quarters > 2 > balance Sheet > short Term Investments
0
Quarters > 2 > balance Sheet > receivables
0
Quarters > 2 > balance Sheet > inventories
0
Quarters > 2 > balance Sheet > total Current Assets
185236
Quarters > 2 > balance Sheet > property Plant Equipment
0
Quarters > 2 > balance Sheet > total Assets
185236
Quarters > 2 > balance Sheet > payables
657871
Quarters > 2 > balance Sheet > short Term Debt
0
Quarters > 2 > balance Sheet > long Term Debt
0
Quarters > 2 > balance Sheet > total Liabilities
2488477
Quarters > 2 > balance Sheet > equity
-2303241
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-466865
Quarters > 2 > cash Flow > depreciation
0
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-189190
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
0
Quarters > 2 > cash Flow > cash From Financing
265000
Quarters > 2 > cash Flow > net Change In Cash
75810
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.01999995716115545
Quarters > 2 > ratios > PB
-10.236329155307674
Quarters > 2 > ratios > ROE
20.26991530630099
Quarters > 2 > ratios > ROA
-252.0379407890475
Quarters > 2 > ratios > FCF
-189190
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
39
Quarters > 3 > quarter
2018-03-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
0
Quarters > 3 > income Statement > gross Profit
0
Quarters > 3 > income Statement > operating Expenses
618494
Quarters > 3 > income Statement > operating Income
-618494
Quarters > 3 > income Statement > interest Expense
227574
Quarters > 3 > income Statement > pretax Income
-850601
Quarters > 3 > income Statement > net Income
-850601
Quarters > 3 > income Statement > eps
-44.07259067357513
Quarters > 3 > income Statement > dividends Per Share
0
Quarters > 3 > income Statement > shares Outstanding
19300
Quarters > 3 > income Statement > income Tax Expense
0
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-232107
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
109426
Quarters > 3 > balance Sheet > short Term Investments
0
Quarters > 3 > balance Sheet > receivables
0
Quarters > 3 > balance Sheet > inventories
0
Quarters > 3 > balance Sheet > total Current Assets
109426
Quarters > 3 > balance Sheet > property Plant Equipment
0
Quarters > 3 > balance Sheet > total Assets
109426
Quarters > 3 > balance Sheet > payables
406751
Quarters > 3 > balance Sheet > short Term Debt
0
Quarters > 3 > balance Sheet > long Term Debt
0
Quarters > 3 > balance Sheet > total Liabilities
1982630
Quarters > 3 > balance Sheet > equity
-1873204
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-850601
Quarters > 3 > cash Flow > depreciation
0
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
-187348
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
0
Quarters > 3 > cash Flow > cash From Financing
270000
Quarters > 3 > cash Flow > net Change In Cash
82652
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-44.07259067357513
Quarters > 3 > ratios > PB
-0.010406234451773539
Quarters > 3 > ratios > ROE
45.40888232141293
Quarters > 3 > ratios > ROA
-777.329885036463
Quarters > 3 > ratios > FCF
-187348
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
39
Annuals > 0 > quarter
2018-03-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
0
Annuals > 0 > income Statement > gross Profit
0
Annuals > 0 > income Statement > operating Expenses
1348788
Annuals > 0 > income Statement > operating Income
-1348788
Annuals > 0 > income Statement > interest Expense
0
Annuals > 0 > income Statement > pretax Income
-2011773
Annuals > 0 > income Statement > net Income
-2011773
Annuals > 0 > income Statement > eps
-193.81242774566473
Annuals > 0 > income Statement > dividends Per Share
0
Annuals > 0 > income Statement > shares Outstanding
10380
Annuals > 0 > income Statement > income Tax Expense
0
Annuals > 0 > income Statement > EBITDA
-1391813
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-43025
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
109426
Annuals > 0 > balance Sheet > short Term Investments
0
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
0
Annuals > 0 > balance Sheet > total Current Assets
109426
Annuals > 0 > balance Sheet > property Plant Equipment
0
Annuals > 0 > balance Sheet > total Assets
109426
Annuals > 0 > balance Sheet > payables
406751
Annuals > 0 > balance Sheet > short Term Debt
0
Annuals > 0 > balance Sheet > long Term Debt
0
Annuals > 0 > balance Sheet > total Liabilities
1982630
Annuals > 0 > balance Sheet > equity
-1873204
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-2011773
Annuals > 0 > cash Flow > depreciation
0
Annuals > 0 > cash Flow > change In Working Capital
451304
Annuals > 0 > cash Flow > cash From Operations
-623349
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
0
Annuals > 0 > cash Flow > cash From Financing
700500
Annuals > 0 > cash Flow > net Change In Cash
77151
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-193.81242774566473
Annuals > 0 > ratios > PB
-0.005596720912404629
Annuals > 0 > ratios > ROE
107.39743242060129
Annuals > 0 > ratios > ROA
-1838.4780582311332
Annuals > 0 > ratios > FCF
-623349
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
31
Annuals > 1 > quarter
2017-03-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
0
Annuals > 1 > income Statement > gross Profit
0
Annuals > 1 > income Statement > operating Expenses
1069269
Annuals > 1 > income Statement > operating Income
-1069269
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-1112138
Annuals > 1 > income Statement > net Income
-1112138
Annuals > 1 > income Statement > eps
-
Annuals > 1 > income Statement > dividends Per Share
0
Annuals > 1 > income Statement > shares Outstanding
-
Annuals > 1 > income Statement > income Tax Expense
0
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-42869
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
32275
Annuals > 1 > balance Sheet > short Term Investments
0
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
0
Annuals > 1 > balance Sheet > total Current Assets
33523
Annuals > 1 > balance Sheet > property Plant Equipment
0
Annuals > 1 > balance Sheet > total Assets
33523
Annuals > 1 > balance Sheet > payables
77893
Annuals > 1 > balance Sheet > short Term Debt
0
Annuals > 1 > balance Sheet > long Term Debt
0
Annuals > 1 > balance Sheet > total Liabilities
887445
Annuals > 1 > balance Sheet > equity
-853922
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-1112138
Annuals > 1 > cash Flow > depreciation
201.87
Annuals > 1 > cash Flow > change In Working Capital
-
Annuals > 1 > cash Flow > cash From Operations
-973120
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
0
Annuals > 1 > cash Flow > cash From Financing
953285
Annuals > 1 > cash Flow > net Change In Cash
-19835
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-
Annuals > 1 > ratios > PB
-
Annuals > 1 > ratios > ROE
130.2388274338874
Annuals > 1 > ratios > ROA
-3317.53721325657
Annuals > 1 > ratios > FCF
-973120
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
41
Annuals > 2 > quarter
2016-03-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
0
Annuals > 2 > income Statement > gross Profit
0
Annuals > 2 > income Statement > operating Expenses
840937
Annuals > 2 > income Statement > operating Income
-840937
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-751328
Annuals > 2 > income Statement > net Income
-751328
Annuals > 2 > income Statement > eps
-
Annuals > 2 > income Statement > dividends Per Share
0
Annuals > 2 > income Statement > shares Outstanding
-
Annuals > 2 > income Statement > income Tax Expense
0
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
89609
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
52110
Annuals > 2 > balance Sheet > short Term Investments
0
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
0
Annuals > 2 > balance Sheet > total Current Assets
52110
Annuals > 2 > balance Sheet > property Plant Equipment
0
Annuals > 2 > balance Sheet > total Assets
52110
Annuals > 2 > balance Sheet > payables
47498
Annuals > 2 > balance Sheet > short Term Debt
0
Annuals > 2 > balance Sheet > long Term Debt
0
Annuals > 2 > balance Sheet > total Liabilities
421894
Annuals > 2 > balance Sheet > equity
-369784
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-751328
Annuals > 2 > cash Flow > depreciation
320.59
Annuals > 2 > cash Flow > change In Working Capital
-
Annuals > 2 > cash Flow > cash From Operations
-564660
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
0
Annuals > 2 > cash Flow > cash From Financing
616561
Annuals > 2 > cash Flow > net Change In Cash
51901
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-
Annuals > 2 > ratios > PB
-
Annuals > 2 > ratios > ROE
203.1802349479696
Annuals > 2 > ratios > ROA
-1441.8115524851275
Annuals > 2 > ratios > FCF
-564660
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
40
Annuals > 3 > quarter
2015-03-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
0
Annuals > 3 > income Statement > gross Profit
0
Annuals > 3 > income Statement > operating Expenses
29681
Annuals > 3 > income Statement > operating Income
-29681
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
78304
Annuals > 3 > income Statement > net Income
78304
Annuals > 3 > income Statement > eps
-
Annuals > 3 > income Statement > dividends Per Share
0
Annuals > 3 > income Statement > shares Outstanding
-
Annuals > 3 > income Statement > income Tax Expense
0
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
107985
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
209
Annuals > 3 > balance Sheet > short Term Investments
0
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
0
Annuals > 3 > balance Sheet > total Current Assets
209
Annuals > 3 > balance Sheet > property Plant Equipment
0
Annuals > 3 > balance Sheet > total Assets
209
Annuals > 3 > balance Sheet > payables
214
Annuals > 3 > balance Sheet > short Term Debt
0
Annuals > 3 > balance Sheet > long Term Debt
0
Annuals > 3 > balance Sheet > total Liabilities
218665
Annuals > 3 > balance Sheet > equity
-218456
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
78304
Annuals > 3 > cash Flow > depreciation
460.5
Annuals > 3 > cash Flow > change In Working Capital
-
Annuals > 3 > cash Flow > cash From Operations
179
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
0
Annuals > 3 > cash Flow > cash From Financing
616561
Annuals > 3 > cash Flow > net Change In Cash
179
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-
Annuals > 3 > ratios > PB
-
Annuals > 3 > ratios > ROE
-35.84428901014392
Annuals > 3 > ratios > ROA
37466.02870813397
Annuals > 3 > ratios > FCF
179
Annuals > 3 > ratios > Piotroski FScore
2
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
55
Valuation > metrics > PE
19.598114285714285
Valuation > metrics > PB
-0.009357228545079341
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-18.156835091486432
Profitability > metrics > ROA
105.24624774834213
Profitability > final Score
45
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-0.6917972350230415
Risk > final Score
27
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.3465409948513674
Liquidity > metrics > Quick Ratio
1.3465409948513674
Liquidity > final Score
84
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
55
Prev Profitabilities > 1
55
Prev Profitabilities > 2
55
Prev Risks > 0
27
Prev Risks > 1
27
Prev Risks > 2
19
Prev Liquidities > 0
13
Prev Liquidities > 1
24
Prev Liquidities > 2
23
Updated At
2026-01-20T21:40:10.559Z
Earnings History > 0 > period
2019-03-31
Earnings History > 0 > report Date
2019-06-17
Earnings History > 0 > date
2019-03-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
USD
Earnings History > 0 > eps Actual
19.63
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
19.63
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2018-12-31
Earnings History > 1 > report Date
2018-12-31
Earnings History > 1 > date
2018-12-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
USD
Earnings History > 1 > eps Actual
19.6279
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2018-09-30
Earnings History > 2 > report Date
2018-11-13
Earnings History > 2 > date
2018-09-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
USD
Earnings History > 2 > eps Actual
-0.01
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2018-06-30
Earnings History > 3 > report Date
2018-07-16
Earnings History > 3 > date
2018-06-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-0.02
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2018-03-31
Earnings History > 4 > report Date
2018-06-30
Earnings History > 4 > date
2018-03-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-44.019
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2017-12-31
Earnings History > 5 > report Date
2018-02-20
Earnings History > 5 > date
2017-12-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.02
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2017-09-30
Earnings History > 6 > report Date
2017-11-14
Earnings History > 6 > date
2017-09-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.01
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2017-06-30
Earnings History > 7 > report Date
2017-06-30
Earnings History > 7 > date
2017-06-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-65.2474
Earnings History > 7 > eps Estimate
-
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2017-03-31
Earnings History > 8 > report Date
2017-03-31
Earnings History > 8 > date
2017-03-31
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-60.7
Earnings History > 8 > eps Estimate
-
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2016-12-31
Earnings History > 9 > report Date
2016-12-31
Earnings History > 9 > date
2016-12-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-42.4001
Earnings History > 9 > eps Estimate
-
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2016-09-30
Earnings History > 10 > report Date
2016-09-30
Earnings History > 10 > date
2016-09-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-54.7562
Earnings History > 10 > eps Estimate
-
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2016-06-30
Earnings History > 11 > report Date
2016-06-30
Earnings History > 11 > date
2016-06-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-49.5923
Earnings History > 11 > eps Estimate
-
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2016-03-31
Earnings History > 12 > report Date
2016-03-31
Earnings History > 12 > date
2016-03-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-80.5985
Earnings History > 12 > eps Estimate
-
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2015-12-31
Earnings History > 13 > report Date
2015-12-31
Earnings History > 13 > date
2015-12-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
-12.5364
Earnings History > 13 > eps Estimate
-
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
-
Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACTBO stock $1.01 14 Jan 2026 PNK hours: Oversold bounce may aid short entry Meyka
Read more →(Last Updated 2018-12-31)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very High
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of Cantabio Pharmaceuticals Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2019-03-31
EPS Actual
19.63
EPS Estimate
0
EPS Difference
19.63
Surprise Percent
0%
(Last Updated 2018-12-31)
(Last Updated 2018-12-31)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2018-12-31)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2018-12-31)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.